Neoadjuvant chemotherapy equalizes the optimal cytoreduction rate to primary surgery without improving survival in advanced ovarian cancer

Sadeleştirilmiş öğe sayfası
dc.contributor.authorTaskin, Salih
dc.contributor.authorGungor, Mete
dc.contributor.authorOrtac, Firat
dc.contributor.authorOztuna, Derya
dc.date.accessioned2025-10-16T15:33:54Z
dc.date.issued2013
dc.identifier.doi10.1007/s00404-013-2924-7
dc.identifier.otherWOS:000326884700035
dc.identifier.urihttps://openaccess.acibadem.edu.tr/handle/11443/9302
dc.publisherSPRINGER HEIDELBERG
dc.sourceARCHIVES OF GYNECOLOGY AND OBSTETRICS
dc.subjectNeoadjuvant chemotherapy
dc.subjectOvarian cancer
dc.subjectOptimal cytoreduction
dc.subjectSurvival
dc.titleNeoadjuvant chemotherapy equalizes the optimal cytoreduction rate to primary surgery without improving survival in advanced ovarian cancer
dc.typeArticle

Dosyalar

Koleksiyonlar

WOS